KR20020089817A - 조혈기능 증진 및 방사선 방호용 생약추출물 - Google Patents
조혈기능 증진 및 방사선 방호용 생약추출물 Download PDFInfo
- Publication number
- KR20020089817A KR20020089817A KR1020010028743A KR20010028743A KR20020089817A KR 20020089817 A KR20020089817 A KR 20020089817A KR 1020010028743 A KR1020010028743 A KR 1020010028743A KR 20010028743 A KR20010028743 A KR 20010028743A KR 20020089817 A KR20020089817 A KR 20020089817A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- radiation
- herbal extract
- extract
- hematopoietic
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 230000005855 radiation Effects 0.000 title claims description 61
- 230000003416 augmentation Effects 0.000 title 1
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 37
- 230000036737 immune function Effects 0.000 claims abstract description 21
- 241000382455 Angelica sinensis Species 0.000 claims abstract 3
- 239000012676 herbal extract Substances 0.000 claims description 97
- 241000736199 Paeonia Species 0.000 claims description 26
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 26
- 241000411851 herbal medicine Species 0.000 claims description 20
- 241001572175 Gaza Species 0.000 claims description 13
- 241000125175 Angelica Species 0.000 claims description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 210000000130 stem cell Anatomy 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 4
- 210000000777 hematopoietic system Anatomy 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 230000001172 regenerating effect Effects 0.000 abstract description 4
- 241000244365 Ligusticum sinense Species 0.000 abstract 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 2
- 235000002634 Solanum Nutrition 0.000 abstract 2
- 241000207763 Solanum Species 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 210000000683 abdominal cavity Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 44
- 230000000694 effects Effects 0.000 description 38
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 16
- 210000000601 blood cell Anatomy 0.000 description 15
- 210000002798 bone marrow cell Anatomy 0.000 description 15
- 210000000813 small intestine Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000000735 allogeneic effect Effects 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 241000283074 Equus asinus Species 0.000 description 8
- 206010073306 Exposure to radiation Diseases 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 101100042788 Caenorhabditis elegans him-1 gene Proteins 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 208000018706 hematopoietic system disease Diseases 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 210000002536 stromal cell Anatomy 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 231100000111 LD50 Toxicity 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000008616 guibi-tang Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000009536 samultang Substances 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000019095 Radiation-induced disease Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000015322 bone marrow disease Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AZFYOKHCKZPHNU-JJJJRQIZSA-N 2-aminoethyl carbamimidothioate;[[(2r,3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound NCCSC(N)=N.C1=NC=2C(N)=NC=NC=2N1C1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O AZFYOKHCKZPHNU-JJJJRQIZSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010038460 Renal haemorrhage Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000012888 dietary physiology Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
- 당귀 10-35 중량부, 천궁 10-35 중량부, 작약 10-35 중량부 및 가자 10-35 중량부를 포함하는 생약 추출물.
- 제 1항에 있어서, 당귀, 천궁, 작약 및 가자는 동일 무게 비율로 포함되는 것을 특징으로 하는 생약추출물.
- 제 1항의 생약추출물을 유효성분으로 함유하는 조혈기능 증강용 약학적 조성물 또는 기능성 식품.
- 제 1항의 생약추출물을 유효성분으로 함유하는 면역기능 증강용 약학적 조성물 또는 기능성 식품.
- 제 1항의 생약추출물을 유효성분으로 함유하는 방사선 방호용 약학적 조성물 또는 기능성 식품.
- 1) 당귀, 천궁, 작약 및 가자로 이루어진 혼합 생약재에 혼합 생약재 총 무게의 5 내지 20배의 물을 가하는 단계;2) 상기의 혼합물을 가열하여 추출하는 단계; 및3) 상기의 추출물을 농축하는 단계로 구성되는 제 1항의 생약추출물의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0028743A KR100440863B1 (ko) | 2001-05-24 | 2001-05-24 | 조혈기능 증진 및 방사선 방호용 생약추출물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0028743A KR100440863B1 (ko) | 2001-05-24 | 2001-05-24 | 조혈기능 증진 및 방사선 방호용 생약추출물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0080989A Division KR100449655B1 (ko) | 2003-11-17 | 2003-11-17 | 조혈 및 면역기능 증강 및 방사선 방호용 기능성 식품 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020089817A true KR20020089817A (ko) | 2002-11-30 |
KR100440863B1 KR100440863B1 (ko) | 2004-07-19 |
Family
ID=27706323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0028743A KR100440863B1 (ko) | 2001-05-24 | 2001-05-24 | 조혈기능 증진 및 방사선 방호용 생약추출물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100440863B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100697212B1 (ko) * | 2005-01-29 | 2007-03-22 | 서울향료(주) | 황기 및 당귀의 혼합 생약재 추출물을 유효성분으로 하는,항암제 투여에 의해 유발되는 부작용 치료용 조혈 촉진제 |
WO2010077867A3 (en) * | 2008-12-15 | 2010-11-25 | Ecopharm, Llc | Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus |
CN102940702A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 一种治疗心脑血管病的药物组合物 |
KR101652730B1 (ko) * | 2015-10-08 | 2016-09-01 | 한국원자력연구원 | 지용성 폴리페놀 성분이 증가된 생약 조성물 제조방법, 상기 방법으로 제조된 생약 조성물, 및 이의 용도 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101350144B1 (ko) * | 2013-05-03 | 2014-01-10 | 재단법인 통합의료진흥원 | 팔물탕 추출물을 포함하는 골수유래 줄기세포 증식 촉진용 조성물 |
KR102070967B1 (ko) * | 2013-12-10 | 2020-01-29 | 한국한의학연구원 | 사군자탕을 유효성분으로 포함하는, 세포의 유도만능줄기세포로의 리프로그래밍 촉진용 조성물 및 이를 이용한 유도만능줄기세포의 제조방법 |
-
2001
- 2001-05-24 KR KR10-2001-0028743A patent/KR100440863B1/ko active IP Right Grant
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100697212B1 (ko) * | 2005-01-29 | 2007-03-22 | 서울향료(주) | 황기 및 당귀의 혼합 생약재 추출물을 유효성분으로 하는,항암제 투여에 의해 유발되는 부작용 치료용 조혈 촉진제 |
WO2010077867A3 (en) * | 2008-12-15 | 2010-11-25 | Ecopharm, Llc | Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus |
US8137710B2 (en) | 2008-12-15 | 2012-03-20 | EcoPharm Corporation | Treating idiopathic thrombocytopenic purpura with comprising extracts of Astragalus membranaceus |
US8728543B2 (en) | 2008-12-15 | 2014-05-20 | EcoPharm Corporation | Methods of treating idiopathic thrombocytopenic purpura with compositions comprising extracts of Astragalus membranaceus |
CN102940702A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 一种治疗心脑血管病的药物组合物 |
KR101652730B1 (ko) * | 2015-10-08 | 2016-09-01 | 한국원자력연구원 | 지용성 폴리페놀 성분이 증가된 생약 조성물 제조방법, 상기 방법으로 제조된 생약 조성물, 및 이의 용도 |
WO2017061840A1 (ko) * | 2015-10-08 | 2017-04-13 | 한국원자력연구원 | 지용성 폴리페놀 성분이 증가된 생약 조성물 제조방법, 상기 방법으로 제조된 생약 조성물, 및 이의 용도 |
US10736929B2 (en) | 2015-10-08 | 2020-08-11 | Korea Atomic Energy Research Institute | Method for preparing herbal composition having increased fat-solublepolyphenol content, herbal composition prepared thereby and use thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100440863B1 (ko) | 2004-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3546570A2 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
KR101834872B1 (ko) | 담팔수 추출물 또는 이의 분획물을 유효 성분으로 포함하는 알파 계열 허피스 바이러스 감염증의 예방 또는 치료용 약제학적 조성물 | |
JP4055951B2 (ja) | 抗癌、免疫及び造血機能増進効果と酸化的生体損傷の抑制効果を持った生薬組成物とその製造方法 | |
KR100440863B1 (ko) | 조혈기능 증진 및 방사선 방호용 생약추출물 | |
KR20000061327A (ko) | 간질환 예방 및 치료용 생약조성물 | |
KR100506396B1 (ko) | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 | |
KR100449655B1 (ko) | 조혈 및 면역기능 증강 및 방사선 방호용 기능성 식품 | |
KR100401955B1 (ko) | 면역, 조혈기능 증진 및 방사선 방호용 생약조성물 및그의 제조방법 | |
Subramoniam et al. | Inhibition of antigen-induced degranulation of sensitized mast cells by Trichopus zeylanicus in mice and rats | |
KR20140145570A (ko) | 땅꽈리 추출물을 포함하는 혈관내피세포 노화로 유발되는 질병의 예방 또는 치료용 약학적 조성물 | |
EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
KR100436428B1 (ko) | 간세포 보호 및 간 손상 예방 또는 치료 활성을 나타내는연자육 추출물 및 이를 포함하는 조성물 | |
CN113134034A (zh) | 一种中药组合物、应用及中药制剂 | |
KR20150105561A (ko) | 헛개나무 추출물을 함유하는 골 질환의 예방 또는 치료용 약학적 조성물 | |
KR100529991B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물 | |
JPH0930983A (ja) | アポトーシス抑制剤 | |
KR20140001319A (ko) | 밀리타리스 동충하초 추출물 제조방법, 이에 따라 제조된 밀리타리스 동충하초 추출물을 포함하는 암 예방 및 치료용 약학 조성물 및 건강보조식품 | |
CN116270787B (zh) | 一种中西复方药物在制备治疗白血病药物中的应用 | |
US20040076618A1 (en) | Placental preparation having antitumor activity | |
KR101209646B1 (ko) | 야베스 추출물을 포함하는 면역세포증가 또는 암세포 전이 억제 또는 간염 바이러스 증식 억제용 약학적 조성물 | |
KR100510429B1 (ko) | 면역활성 증진 및 항암 효과를 갖는 혼합물의 물추출물 및그의 제조방법 | |
Gopalakrishnan et al. | Antihepatotoxic acticity of Coccinia indica | |
KR20170041997A (ko) | 섬오갈피 추출물을 함유하는 혈관질환의 예방 또는 치료용 조성물 | |
KR20240079612A (ko) | 팥 추출물을 포함하는 비알코올성 지방간 예방, 개선 또는 치료용 조성물 | |
JPH0672888A (ja) | アポトーシス誘起剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130709 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140630 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150707 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160711 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170620 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190613 Year of fee payment: 16 |